Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma

• Published in: The New England journal of medicine Vol. 378; no. 26; pp. 2475 - 2485
• Main Authors: Rabe, Klaus F, Nair, Parameswaran, Brusselle, Guy, Maspero, Jorge F, Castro, Mario, Sher, Lawrence, Zhu, Hongjie, Hamilton, Jennifer D, Swanson, Brian N, Khan, Asif, Chao, Jingdong, Staudinger, Heribert, Pirozzi, Gianluca, Antoni, Christian, Amin, Nikhil, Ruddy, Marcella, Akinlade, Bolanle, Graham, Neil M.H, Stahl, Neil, Yancopoulos, George D, Teper, Ariel
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 28.06.2018
• Subjects: Administration, Oral; Adolescent; Adult; Anti-Asthmatic Agents - adverse effects; Anti-Asthmatic Agents - pharmacology; Anti-Asthmatic Agents - therapeutic use; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal - pharmacology; Antibodies, Monoclonal - therapeutic use; Asthma; Asthma - classification; Asthma - drug therapy; Biomarkers; Bronchodilators; Child; Cytokines; Dermatitis; Double-Blind Method; Drug Therapy, Combination; Eosinophilia; Eosinophilia - chemically induced; Female; Forced Expiratory Volume - drug effects; Glucocorticoids; Glucocorticoids - administration & dosage; Humans; Immunotherapy; Inflammation; Injections, Subcutaneous - adverse effects; Intention to Treat Analysis; Interleukin 13; Interleukin 4; Logistic Models; Male; Middle Aged; Monoclonal antibodies; Patient safety; Patients; Population; Receptors, Interleukin-4 - antagonists & inhibitors; Signal transduction; Young Adult; Germany
• ISSN: 0028-4793; 1533-4406
• DOI: 10.1056/NEJMoa1804093

Patients who used oral glucocorticoids for asthma were able to reduce the dose of treatment more successfully when dupilumab, a monoclonal antibody targeting signaling through the interleukin-4 and interleukin-13 receptor, was added to their regimen than when placebo was added.